Physician profile
Christopher E Nicholls
NPI 1528025855
$3,007.16
in general payments reported to CMS, 2019-2025
28 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $304 · 2021: $361 · 2022: $408 · 2023: $160 · 2024: $1,167 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $914 · Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $914.00 |
| Food and Beverage | $604.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $914.00 | 2024 | |
| Abbvie INC. | $765.37 | 2019-2024 | |
| Astellas Pharma US INC | $285.22 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $117.90 | 2019-2022 | |
| Pfizer INC. | $84.10 | 2019-2025 | |
| Therapeuticsmd, INC. | $78.11 | 2019-2022 | |
| Amgen INC. | $77.79 | 2019-2023 | Evenity, Prolia |
| Exeltis, USA INC. | $75.60 | 2022-2024 | Slynd |
| Sage Therapeutics, LLC | $74.81 | 2024-2025 | Zurzuvae |
| Millicent US INC | $47.22 | 2025 | Intrarosa, Femring |
| Coopersurgical, INC. | $43.52 | 2020-2024 | Summit Doppler |
| Scynexis, INC. | $41.28 | 2022 | |
| Lilly USA, LLC | $40.94 | 2021-2024 | Zepbound |
| Dexcom, INC. | $36.64 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $36.10 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $34.67 | 2022-2023 | Nexplanon |
| Novo Nordisk INC | $32.75 | 2019-2021 | |
| Duchesnay USA Incorporated | $30.83 | 2019 | |
| Myovant Sciences INC. | $25.45 | 2022 | |
| Baxter Healthcare | $24.81 | 2022 | |
| Solventum Corporation | $24.12 | 2025 | Prevena |
| Mayne Pharma Commercial LLC | $23.62 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.26 | 2023 | Trulance, Xifaxan |
| Shire North American Group INC | $16.65 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.19 | 2022 | |
| Shield Therapeutics INC | $13.42 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $13.41 | 2023 | Myfembree |
| Allergan, INC. | $13.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nicholls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.